Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsColorado Rocky Mountain RNA Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedColorado Rocky Mountain Health PlansPolicy 2026D0072P

    RNA-Targeted Therapies (Amvuttra and Onpattro)

    Customize your policy alerts

    Sign up for Colorado Rocky Mountain Health Plans Policy 2026D0072P alerts

    Get alerted when Policy 2026D0072P changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-benefit coverage and prior authorization for Amvuttra (vutrisiran) and Onpattro (patisiran) for UnitedHealthcare Commercial and Individual Exchange members. Coverage criteria address ATTR cardiomyopathy and hereditary ATTR polyneuropathy, including initial and continuation therapy.

    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyRNA-Targeted Therapies (Amvuttra and Onpattro)
    Policy CodePolicy 2026D0072P
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation for medically necessary uses; initial and continuation authorizations are limited to 12 months.
    SourceLink
    POLICY UPDATE CHANGES

    Wainua (eplontersen) was added to the Review at Launch program, and some members may not be eligible for coverage at this time.

    HCPCS codes C9311, J3490, and J3590 were added to the applicable codes section.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    2RNA-targeted therapies covered
    12 monthsMaximum authorization period
    NYHA I-IIIATTR-CM heart-failure classes
    3HCPCS codes added
    2Explicitly noncovered disease categories

    Medical Necessity and Coverage Rules

    Amvuttra for ATTR cardiomyopathy

    Amvuttra is medically necessary for ATTR cardiomyopathy when all applicable initial-therapy or continuation-therapy criteria are met.

    ONE of

    • Initial therapy

      • Diagnosis and confirmation

        • ATTR-CM diagnosis

          • Diagnosis of wild-type or hereditary transthyretin-mediated amyloidosis with cardiomyopathy.
        • ONE qualifying confirmation pathway

          • Pathogenic TTR mutation, such as V30M.
          • Cardiac or noncardiac tissue biopsy demonstrating histologic confirmation of ATTR amyloid deposits.
          • Imaging confirmation

            • Echocardiogram or cardiac magnetic resonance imaging suggestive of amyloidosis.
            • Radionuclide imaging with 99mTc-DPD, 99mTc-PYP, or 99mTc-HMDP showing grade 2 or 3 cardiac uptake.
            • Absence of light-chain amyloidosis.
      • Clinical disease requirements

        • NYHA Functional Class I, II, or III heart failure.NYHA I-III
        • Physician attestation that the NT-proBNP level, when combined with signs and symptoms, is definitive for ATTR-CM.
        • ONE

          • History of heart failure with at least one prior hospitalization for heart failure.
          • Current signs and symptoms of heart failure, such as dyspnea or edema.
      • Documentation of progressive worsening or an event resulting in hospitalization related to hATTR-mediated ATTR-CM while receiving Vyndaqel, Vyndamax, or Attruby.

        For Medicare reviews, refer to the CMS section.

      • Treatment and prescribing requirements

        • Amvuttra is not being administered in combination with another RNA-interference agent or a transthyretin stabilizer.
        • Prescribed by or in consultation with a cardiologist.
        • Dosing follows FDA prescribing information.
        • Initial authorization is for no more than 12 months.12 months maximum
    • Continuation therapy

      • Patient previously received Amvuttra for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis.
      • Documentation of a positive clinical response to Amvuttra, such as improved symptoms or quality of life, slowed disease progression, or decreased hospitalizations.
      • Patient continues to have NYHA Functional Class I, II, or III heart failure.NYHA I-III
      • Amvuttra is not being administered in combination with another RNA-interference agent or a transthyretin stabilizer.
      • Prescribed by or in consultation with a cardiologist.
      • Dosing follows FDA prescribing information.

    Initial therapy for hATTR polyneuropathy

    Amvuttra or Onpattro is medically necessary for initial treatment of hATTR polyneuropathy when all of the following applicable criteria are met.

    ALL of the following

    • Diagnosis and genetic confirmation

      • Diagnosis of hATTR amyloidosis with polyneuropathy.
      • Documentation of a pathogenic TTR mutation, such as V30M.
    • ONE qualifying clinical pathway

      • Disease-severity pathway

        • ONE baseline measure

          • Baseline polyneuropathy disability (PND) score ≤ IIIb.

    Continuation therapy for hATTR polyneuropathy

    Continuation therapy for Amvuttra or Onpattro is medically necessary when all of the following criteria are met.

    ALL of the following

    • Patient previously received treatment with Amvuttra or Onpattro.
    • ONE ongoing disease-severity measure

      • Continued PND score ≤ IIIb.PND ≤ IIIb
      • Continued FAP stage 1 or 2.FAP stage 1 or 2
      • Continued NIS score ≥ 5 and ≤ 130.NIS 5-130

    Amvuttra and Onpattro are unproven and not medically necessary for sensorimotor or autonomic neuropathy that is not related to hATTR amyloidosis. They are also not medically necessary for primary or leptomeningeal amyloidosis.

    FDA approval alone is not a basis for coverage. Coverage requires that the requested treatment meet the applicable medical-necessity criteria in this policy.

    A patient with hATTR polyneuropathy who has had a liver transplant does not meet the policy’s medical-necessity criteria for treatment.

    The requested RNA-interference therapy must not be used in combination with another RNA-interference agent or a transthyretin stabilizer. Examples include Amvuttra, Onpattro, Wainua, or Tegsedi, and Vyndaqel or Vyndamax, respectively. Concurrent use does not meet medical-necessity criteria.

    Initial Authorization Criteria

    Amvuttra ATTR cardiomyopathy initial therapy

    Amvuttra initial therapy for ATTR cardiomyopathy is medically necessary when all of the following criteria are met.

    ALL of the following

    • Diagnosis of wild-type or hereditary transthyretin-mediated amyloidosis with cardiomyopathy, with one qualifying confirmation pathway: pathogenic TTR mutation; cardiac or noncardiac tissue biopsy demonstrating ATTR amyloid deposits; or echocardiogram/cardiac MRI suggestive of amyloidosis together with grade 2 or 3 uptake on 99mTc-DPD, 99mTc-PYP, or 99mTc-HMDP imaging and absence of light-chain amyloidosis.
    • NYHA Functional Class I, II, or III heart failure.NYHA I-III
    • Physician attestation that the NT-proBNP level, when combined with signs and symptoms, is definitive for ATTR-CM.

    Continuation Authorization Criteria

    Amvuttra ATTR cardiomyopathy continuation

    Amvuttra continuation therapy for ATTR cardiomyopathy is medically necessary when all of the following criteria are met.

    ALL of the following

    • Patient previously received Amvuttra for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis.
    • Documentation of a positive clinical response to Amvuttra, such as improved symptoms or quality of life, slowed disease progression, or decreased hospitalizations.
    • Patient continues to have NYHA Functional Class I, II, or III heart failure.NYHA I-III
    • Amvuttra is not administered in combination with another RNA-interference agent or a transthyretin stabilizer.

    Codes and Clinical Thresholds

    HCPCS CodesHCPCS
    C9311Injection, eplontersen, 1 mg
    J0222Injection, patisiran, 0.1 mg
    J3490Unclassified drugs
    J3590Unclassified biologics
    Diagnosis CodesICD-10
    E85.0Non-neuropathic heredofamilial amyloidosis
    E85.1Neuropathic heredofamilial amyloidosis
    E85.4Organ-limited amyloidosis
    E85.82Wild-type transthyretin-related (ATTR) amyloidosis
    Applicable CodesHCPCS
    C9311Description not provided in the document
    J3490Description not provided in the document
    J3590Description not provided in the document
    NYHA Heart-Failure Functional Class
    MeasureNYHA heart-failure functional class
    Qualifying classesI, II, or III
    Applies toATTR cardiomyopathy initial and continuation therapy
    Polyneuropathy Disability Score
    MeasurePolyneuropathy disability (PND) score
    Qualifying thresholdNo greater than IIIb (≤ IIIb)
    Applies to

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization and Authorization Duration

    Prior authorization may be required for Amvuttra (vutrisiran) and Onpattro (patisiran) for covered ATTR cardiomyopathy or hATTR polyneuropathy indications. Submit the required clinical documentation, and request authorization consistent with the applicable treatment phase and FDA-prescribing-information dosing.

    • Initial authorization and continuation authorization are each limited to no more than 12 months.
    • The applicable specialist must prescribe or be consulted: a cardiologist for ATTR cardiomyopathy and a neurologist for hATTR polyneuropathy.
    Step Therapy

    Required Prior Therapy for ATTR Cardiomyopathy

    For initial Amvuttra therapy for ATTR cardiomyopathy, document progressive worsening or an event resulting in hospitalization related to hATTR-mediated ATTR cardiomyopathy while the patient was receiving required prior therapy.

    • Required prior therapy: Vyndaqel (tafamidis meglumine), Vyndamax (tafamidis), or Attruby (acoramidis).

    Required Prior Therapy Pathways

    IndicationRequired prior therapyAdditional requirementCoverage
    ATTR cardiomyopathy initial-therapy pathwayVyndaqel, Vyndamax, or AttrubyDocumented progressive worsening or an event resulting in hospitalization related to hATTR-mediated ATTR-CM while receiving the prior therapyRequired
    IndicationAlternative step-therapy requirementPathway relationshipCoverage
    hATTR polyneuropathy initial-therapy pathwayDocumented intolerance or contraindication to both a tafamidis product (Vyndaqel or Vyndamax) and AttrubyAlternative to the clinical-severity pathway requiring a qualifying baseline measure and clinical signs and symptomsPermitted alternative

    Disease Background

    ATTR amyloidosis occurs when transthyretin protein misfolds and forms amyloid fibrils that deposit in organs such as the nerves and heart. The disease may be wild-type or hereditary and can cause restrictive cardiomyopathy or progressive polyneuropathy. Amvuttra (vutrisiran) and Onpattro (patisiran) are small-interfering RNA therapies directed to the liver that reduce production of wild-type and variant transthyretin.

    Clinical Definitions

    ATTR-CM
    TermATTR-CM
    DefinitionTransthyretin-mediated amyloidosis involving the heart, with cardiomyopathy
    Types includedWild-type (wtATTR) or hereditary (hATTR) ATTR amyloidosis
    wtATTR
    TermwtATTR
    DefinitionWild-type transthyretin amyloidosis
    Typical associationOften associated with aging rather than an inherited TTR mutation
    Policy Summary
    PayerColorado Rocky Mountain Health Plans
    PolicyRNA-Targeted Therapies (Amvuttra and Onpattro)
    Policy CodePolicy 2026D0072P
    Change TypeModified
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation for medically necessary uses; initial and continuation authorizations are limited to 12 months.
    SourceLink
    On This Page
    Medical Necessity and Coverage RulesInitial Authorization CriteriaContinuation Authorization CriteriaCodes and Clinical ThresholdsAuthorization, Documentation, and Denial RisksRequired Prior Therapy PathwaysDisease BackgroundClinical Definitions
  1. Authorization is for no more than 12 months.12 months maximum
  2. PND ≤ IIIb
  3. Baseline familial amyloid polyneuropathy (FAP) stage 1 or 2.FAP stage 1 or 2
  4. Baseline neuropathy impairment score (NIS) ≥ 5 and ≤ 130.NIS 5-130
  5. Baseline Karnofsky performance status (KPS) score ≥ 60%.KPS ≥ 60%
  6. Clinical signs and symptoms of hATTR polyneuropathy, such as peripheral sensorimotor polyneuropathy, autonomic neuropathy, or motor disability.
  7. Alternative intolerance pathway

    • Documented intolerance or contraindication to both Vyndaqel or Vyndamax and Attruby.
  8. Patient has not had a liver transplant.
  9. The requested therapy is not administered in combination with another RNA-interference agent or a transthyretin stabilizer.
  10. Prescribed by or in consultation with a neurologist.
  11. Dosing follows FDA prescribing information.
  12. Initial authorization is for no more than 12 months.12 months maximum
  13. Continued KPS score ≥ 60%.KPS ≥ 60%
  14. Documentation of a positive clinical response to Amvuttra or Onpattro, such as improved neurologic impairment, motor function, or quality of life, or slowed disease progression.
  15. The requested therapy is not administered in combination with another RNA-interference agent or a transthyretin stabilizer.
  16. Prescribed by or in consultation with a neurologist.
  17. Dosing follows FDA prescribing information.
  18. Authorization is for no more than 12 months.12 months maximum
  19. History of heart failure with at least one prior hospitalization for heart failure, or current signs and symptoms of heart failure such as dyspnea or edema.
  20. Progressive worsening or an event resulting in hospitalization related to hATTR-mediated ATTR-CM while receiving Vyndaqel, Vyndamax, or Attruby.
  21. Amvuttra is not administered in combination with another RNA-interference agent or a transthyretin stabilizer.
  22. Prescribed by or in consultation with a cardiologist.
  23. Dosing follows FDA prescribing information.
  24. Initial authorization is for no more than 12 months.12 months maximum
  25. Amvuttra or Onpattro hATTR polyneuropathy initial therapy

    Amvuttra or Onpattro initial therapy for hATTR polyneuropathy is medically necessary when all of the following criteria are met.

    ALL of the following

    • Diagnosis of hATTR amyloidosis with polyneuropathy and documentation of a pathogenic TTR mutation.
    • ONE qualifying clinical pathway

      • Disease-severity pathway

        • ONE baseline measure

          • Baseline PND score ≤ IIIb.PND ≤ IIIb
          • Baseline FAP stage 1 or 2.FAP stage 1 or 2
          • Baseline NIS score ≥ 5 and ≤ 130.NIS 5-130
          • Baseline KPS score ≥ 60%.KPS ≥ 60%
        • Clinical signs and symptoms of hATTR polyneuropathy, such as peripheral sensorimotor polyneuropathy, autonomic neuropathy, or motor disability.
      • Documented intolerance or contraindication to both Vyndaqel or Vyndamax and Attruby.
    • Patient has not had a liver transplant.
    • The requested therapy is not administered in combination with another RNA-interference agent or a transthyretin stabilizer.
    • Prescribed by or in consultation with a neurologist.
    • Dosing follows FDA prescribing information.
    • Initial authorization is for no more than 12 months.12 months maximum
  26. Prescribed by or in consultation with a cardiologist.
  27. Dosing follows FDA prescribing information.
  28. Authorization is for no more than 12 months.12 months maximum
  29. Amvuttra or Onpattro hATTR polyneuropathy continuation

    Amvuttra or Onpattro continuation therapy for hATTR polyneuropathy is medically necessary when all of the following criteria are met.

    ALL of the following

    • Patient previously received treatment with Amvuttra or Onpattro.
    • ONE ongoing disease-severity measure

      • Continued PND score ≤ IIIb.PND ≤ IIIb
      • Continued FAP stage 1 or 2.FAP stage 1 or 2
      • Continued NIS score ≥ 5 and ≤ 130.NIS 5-130
      • Continued KPS score ≥ 60%.KPS ≥ 60%
    • Documentation of a positive clinical response to Amvuttra or Onpattro, such as improved neurologic impairment, motor function, or quality of life, or slowed disease progression.
    • The requested therapy is not administered in combination with another RNA-interference agent or a transthyretin stabilizer.
    • Prescribed by or in consultation with a neurologist.
    • Dosing follows FDA prescribing information.
    • Authorization is for no more than 12 months.12 months maximum
    Baseline or continued hATTR polyneuropathy severity
    Familial Amyloid Polyneuropathy Stage
    MeasureFamilial amyloid polyneuropathy (FAP) stage
    Qualifying stagesStage 1 or 2
    Applies toBaseline or continued hATTR polyneuropathy severity
    Neuropathy Impairment Score
    MeasureNeuropathy impairment score (NIS)
    Qualifying rangeAt least 5 and no more than 130 (≥ 5 and ≤ 130)
    Applies toBaseline or continued hATTR polyneuropathy severity
    Karnofsky Performance Status
    MeasureKarnofsky performance status (KPS) score
    Qualifying thresholdAt least 60% (≥ 60%)
    Applies toBaseline or continued hATTR polyneuropathy severity
  30. The documentation must connect the worsening or hospitalization-related event to the disease while on the prior therapy.
  31. Step Therapy

    Alternative Prior-Therapy Pathway for hATTR Polyneuropathy

    For initial therapy for hATTR polyneuropathy, document either the qualifying clinical-severity pathway or intolerance or contraindication to both required alternative therapies.

    • Clinical-severity pathway: PND score ≤ IIIb, FAP stage 1 or 2, NIS score ≥ 5 and ≤ 130, or KPS score ≥ 60%, together with clinical signs and symptoms of disease.
    • Alternative pathway: documented intolerance or contraindication to both Vyndaqel or Vyndamax and Attruby (acoramidis).
    Documentation Required

    ATTR Cardiomyopathy Diagnostic Documentation

    For ATTR cardiomyopathy, submit documentation confirming wild-type or hereditary ATTR-mediated amyloidosis with cardiomyopathy and the required diagnostic evidence, disease severity, and heart-failure findings.

    • Document a pathogenic TTR mutation, or biopsy evidence of ATTR amyloid deposits, or suggestive echocardiography/cardiac MRI plus grade 2 or 3 radionuclide cardiac uptake and absence of light-chain amyloidosis.
    • Document NYHA Functional Class I, II, or III heart failure and an NT-proBNP level that, with signs and symptoms, is definitive for ATTR-CM.
    • Document a history of heart failure with at least one prior hospitalization or current heart-failure signs and symptoms, such as dyspnea or edema.
    Documentation Required

    hATTR Polyneuropathy Documentation

    For hATTR polyneuropathy, submit documentation of the diagnosis, pathogenic TTR mutation, qualifying baseline severity, and clinical manifestations.

    • Document hATTR amyloidosis with polyneuropathy and a pathogenic TTR mutation, such as V30M.
    • Document at least one qualifying baseline measure: PND ≤ IIIb, FAP stage 1 or 2, NIS ≥ 5 and ≤ 130, or KPS ≥ 60%.
    • Document clinical signs and symptoms, such as peripheral sensorimotor polyneuropathy, autonomic neuropathy, or motor disability.
    Documentation Required

    Continuation Response Documentation

    For continuation authorization, document the prior treatment, an ongoing qualifying disease-severity measure when applicable, and a positive clinical response to therapy.

    • ATTR cardiomyopathy: document prior Amvuttra treatment, continued NYHA Functional Class I, II, or III heart failure, and positive response such as improved symptoms or quality of life, slowed progression, or fewer hospitalizations.
    • hATTR polyneuropathy: document prior Amvuttra or Onpattro treatment, continued qualifying PND, FAP, NIS, or KPS status, and positive response such as improved neurologic impairment or motor function, improved quality of life, or slowed progression.
    Billing Rule

    Verify Benefit Plan and Mandates

    Before applying this policy, verify the member-specific benefit plan and all applicable federal or state mandates.

    • The member-specific benefit plan governs when it differs from or conflicts with this policy.
    • Confirm whether the plan includes the requested benefit and whether any mandate or Medicare coverage guidance affects the determination.
    Denial Risk

    Noncovered Diagnoses and Prohibited Combinations

    Do not submit or approve therapy when an exclusion or prohibited combination applies. Confirm the diagnosis, transplant history, requested product, and concurrent therapies.

    • Amvuttra and Onpattro are not medically necessary for sensorimotor or autonomic neuropathy unrelated to hATTR amyloidosis or for primary or leptomeningeal amyloidosis.
    • A patient with a liver transplant does not meet the hATTR polyneuropathy criteria.
    • Do not combine Amvuttra or Onpattro with another RNA-interference agent or with a transthyretin stabilizer, including Vyndaqel, Vyndamax, or the applicable other listed agents.
    Denial Risk

    Insufficient Diagnostic or Clinical Documentation

    Initial therapy is at risk for denial when required diagnostic confirmation, disease severity, or clinical evidence is absent or incomplete.

    • ATTR-CM: missing diagnosis, TTR mutation or biopsy/imaging evidence, absence of light-chain amyloidosis where applicable, NYHA class, NT-proBNP support, or heart-failure history/signs can prevent approval.
    • hATTR polyneuropathy: missing diagnosis, pathogenic TTR mutation, qualifying severity score, or clinical signs and symptoms can prevent approval.
    • Missing documentation of required prior therapy or the approved alternative intolerance/contraindication pathway can also prevent approval.
    Denial Risk

    Continuation Criteria Not Met

    Continuation therapy is at risk for denial when prior treatment, an ongoing qualifying severity measure, positive response, specialist involvement, dosing, or noncombination requirements are not documented.

    • Document prior Amvuttra treatment for ATTR cardiomyopathy or prior Amvuttra/Onpattro treatment for hATTR polyneuropathy.
    • Document the applicable ongoing NYHA, PND, FAP, NIS, or KPS measure and a positive clinical response.
    • Confirm no prohibited combination, specialist prescribing or consultation, FDA-consistent dosing, and an authorization period of no more than 12 months.
    Note

    FDA Approval Alone Does Not Establish Coverage

    FDA approval alone does not establish coverage under this policy. Coverage determinations must also satisfy the policy criteria and the member-specific benefit plan.

    • FDA indications for Amvuttra and Onpattro are informational and do not replace required coverage documentation.
    Note

    Wainua May Be Unavailable During Review at Launch

    Wainua (eplontersen) has been added to the Review at Launch program and may be unavailable for some members while the medication is under review.

    • Some members may not be eligible for Wainua coverage at this time.
    • Refer to the applicable Review at Launch for New to Market Medications policy for additional details.
    Billing Rule

    Member Benefit Plan Controls

    The member-specific benefit plan document controls the coverage determination when its terms conflict with this policy.

    • Review the member-specific plan before applying the policy.
    • This policy provides guidance for interpreting standard benefit plans and does not replace the governing plan document.
    hATTR
    TermhATTR
    DefinitionHereditary or variant transthyretin-mediated amyloidosis caused by a pathogenic TTR mutation
    Underlying causeA pathogenic mutation of the transthyretin (TTR) gene
    hATTR Polyneuropathy
    TermhATTR polyneuropathy
    DefinitionHereditary transthyretin-mediated amyloidosis affecting peripheral or autonomic nerves
    Related clinical findingsPeripheral sensorimotor polyneuropathy, autonomic neuropathy, or motor disability